anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: genetics, molecular biology. SUBSTANCE: invention relates to vaccine for prevention and control over animal diseases involving pseudorabies virus containing glycoprotein gp 50 and mutation in gene gp 50. Vaccines can be used against Aujeszky&#39;s disease (pseudorabies) or against other animal diseases if mutation is an insertion containing heterological gene that encodes antigen corresponding to this disease. Pseudorabies virus can contain additionally at least one mutation in gene gp 63 or g1. These vaccines can not be transferred from vaccinated to nonvaccinated animals. EFFECT: enhanced effectiveness of vaccines.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an incense stick bundle with an igniting means, capable of igniting the incense bundle easily and surely even in the case of outdoors with wind, or the like, or when having no igniting means.  &lt;P&gt;SOLUTION: This incense stick bundle is provided by arranging a flame-spreading agent on the front surface at an end surface of the tip end part of the incense stick bundle to easily burn the agent, attaching an igniting agent at several positions of the flame-spreading agent for burning the flame-spreading agent by igniting it by using a side firing agent part (for striking) at the inside of a box for housing the incense stick bundle. Also, for safety, the incense stick bundle is fixed with a fixing tape so as not to deviate from the box, and by drawing out the incense stick bundle from an independent small box of the incense stick box, it is ignited. By any chance, e.g. even in the case of being difficult to ignite, it can be ignited by a method for igniting a match at a striking part installed at the outside of the box.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject preparation with stickiness problem resolved and the whole water absorptivity remaining as it is, homogeneous and low in a single dose needed without impairing its disintegrability, leachability and biological availability, and mitigated in the trouble when taken. SOLUTION: This preparation is such one as to contain 0.012-0.12 pt.wt. of microlpowdery polyethylene glycol based on 1 pt.wt. of loxoprofen sodium; wherein the total amount of additives therein is &lt;=2.5 pts.wt. per pt.wt. of loxoprofen sodium. This preparation has no troubles such as adsorption or adherence in its pharmaceutical manufacturing process, being acceptable in various tests as a medicine and also easy-to-take because of its small size.
PROBLEM TO BE SOLVED: To obtain the subject medicine having effect to lower lipid (triglyceride) content in liver and capable of preventing and/or treating hepar adiposum by including a pyrrolecarboxylic acid-derivative as an active ingredient. SOLUTION: This medicine contains a pyrrolecarboxylic acid-derivative shown by the formula [R&lt;1&gt; is H, a 5-25C alkyl or alkenyl; R&lt;2&gt; is H, phenyl, or a 1-10C (substituted) alkyl; R&lt;3&gt; is H, a 5-25C alkyl or alkenyl] (e.g. 4- tridecylpyrrole-2-carboxylic acid), a salt thereof, hydrates of these, or solvates of these, as an active ingredient. The medicine can be prepared for oral and non-oral administration. In the case of oral administration for adult, it is preferable to administered in a dose of 0.01-1000 mg in one or more portions per day. Such administration allows prevention/treatment of diseases such as hepar adiposum, liver fibrosis, and cirrhosis, all of which are considered to be caused by accumulation of lipid in the liver.
Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer&#39;s disease, Huntington&#39;s disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.
PURPOSE:A cosmetic having improved affinity, permeability, dispersibility, and wetting properties to the skin, high safety and stability free from problems of color and smell, containing a purified liquid lanolin and/or hydrogenated purified liquid lanolin having high content of ester component. CONSTITUTION:A cosmetic comprising purified liquid lanolin and/or hydrogenated purified liquid lanolin having &gt;=90wt% content of ester component. In the purified liquid lanolin, color and smell of lanolin, defects of adhesivity, problem of rancidity with time, allergic phenomena considered to be caused by aliphatic alcohol components, etc. are extremely improved. The purified liquid lanolin is obtained by packing an adsorbent such as silica gel, acid clay, etc. into a column, feeding liquid lanolin to it, developing it with n-hexane, etc., collecting partially an ester component. The purified liquid lanolin is further hydrogenated in the presence of Cu or Pd at &lt;=200 deg.C, to give hydrogenated purified liquid lanolin.
A chlorhexidine gluconate-isopropyl alcohol wet wipe product includes a disinfecting solution, a nonwoven fabric and an outer pack. The disinfecting solution further contains chlorhexidine gluconate and purified water. The nonwoven fabric is configured to be impregnated with the disinfecting solution. The outer pack is configured to wrap the chlorhexidine gluconate-isopropyl alcohol wet wipe product and is a multilayer laminated film pack. The disinfecting solution also includes isopropyl alcohol. The disinfecting effect of the disinfecting wet wipe is greatly improved, the stability of the active ingredients in the disinfecting wet wipe is maintained, the effective period is prolonged, and the contents of chlorhexidine gluconate and isopropyl alcohol in the wet wipe solution in the product that act on the consumer&#39;s skin surface is consistent with the labeled amounts and achieve sufficient contents of active ingredients.
Use of flavin derivatives and their salts for preparing a medicament for the treatment of pathologies of the internal limiting membrane (ILM), is claimed. The flavin derivative is riboflavin or roseoflavin, which can be photodynamically degraded by a irradiation from an intra- or extravitreal light source with a wavelength of 500 nm and an effective intensity of 5 mW/cm 2&gt;, after an intravitreal application of the ILM. The ILM or the its adjacent structures are generated by a mechanical stabilization. ACTIVITY : Ophthalmological. Test details are described but no results given. MECHANISM OF ACTION : None given.
4,4&#39;-diaminodiphenylsulphone is a bactericide and anti-inflammatory agent. It is known to have therapeutic activity against leprosy, dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposiís sarcoma, pneumocystis carinii (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. It is also known to have therapeutic activity against memory loss in patients in need of such therapy, including patients suffering from Alzheimer disease and related neurodegenerative disorders. Donepezil hydrochloride (donepezil) is an acetylcholinesterase inhibitor that is currently used for the symptomatic treatment of Alzheimer disease in patients in need of such therapy. It has now been found that combinations of 4,4&#39;-diaminodiphenylsulphone and cholinesterase inhibitors unexpectedly show synergistic effects in the prevention and/or treatment of dementia. The present invention relates to novel compositions and methods of preventing and/or treating dementia using combinations of 4,4&#39;-diaminodiphenylsulphone and a cholinesterase inhibitor (preferably donepezil). The method involves the administration to such individuals a drug composition of 4,4&#39;-diaminodiphenylsulphone and a cholinesterase inhibitor. The invention also relates to a method of preventing and/or treating dementia including senile dementia, that involves the use of this combination of drugs.
A method and apparatus for measuring a patient&#39;s psychotherapy progress is provided. Initial patient mental health is measured by administering a questionnaire measuring three psychological variables. The three psychological variable measures are combined into a mental health index (69). Following a number of sessions of psychotherapy, the patient&#39;s subsequent psychological condition is again measured using the three psychological variables. Patient session records (42) are stored in a large database (20). Patient progress can thus be compared versus patient initial psychlological condition, typical patient outcomes as stored in the database (20), and patient improvement as a function of a number of sessions of psychotherapy can be determined. The system further provides a case manager with a measure of the effectiveness of continued psychotherapy sessions, and a basis of comparison of various psychotherapy providers.
Pharmaceutical antibacterial compositions for oral, topical and parenteral administration comprise fusidic acid (antibiotic ZN-6) or a non-toxic salt thereof and a penicillinase-sensitive penicillin antibiotic or a non-toxic salt thereof.  Specified salts of fusidic acid include those of sodium and diethanolamine (preferred), potassium, ammonium, calcium, magnesium, triethylamine, piperidine, morpholine, cyclohexylamine, monoethanolamine, dibenzyl ethylenediamine, benzyl-b -phenylethylamine and procaine.  The compositions may be in conventional forms, e.g. ointments, aqueous and oily injections, pills, capsules, tablets, enterically coated tablets and tablets in which the active compounds are separated (particularly when the fusidic acid salt is that of a strong base) e.g. layered and &#34;double&#34; tablets prepared from separate granulations, each comprising one of the above types of antibiotic. Optionally, there may also be present antibacterial nitro-furan derivatives and sulphonamides, other antibiotics which are not absorbed in the intestinal canal and sulphamylbenzoic acid derivatives capable of delaying the excretion of penicillins. Specification 930,786 is referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antibody specifically binding to an insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR, and to provide an antigen-binding portion thereof.  &lt;P&gt;SOLUTION: A human anti-IGF-IR antibody includes a chimeric antibody, a bispecific antibody, a derivatized antibody, or a single chain antibody, or a portion of fusion proteins. An isolated heavy and light chain immunoglobulin molecule derived from an anti-IGF-IR antibody, and a nucleic acid molecule encoding the molecule are provided. Preparation of the anti-IGF-IR antibody, a pharmaceutical composition comprising the antibody, and use of the antibody, and the composition thereof for diagnosis and treatment are provided. A gene therapy uses the nucleic acid molecule encoding the heavy and/or light chain immunoglobulin molecule that comprises the human anti-IGF-IR antibody. A non-human transgenic animal expresses the nucleic acid.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Herein is provided a recombinant lentiviral vector preparation, in which the preparation comprises: a) an effective dose of the recombinant lentiviral vector; b) a histidine hydrochloride buffer for keeping a pH value of the preparation in the range of 6.0-8.0; and c) a carbohydrate. The recombinant lentivirus preparation in the present invention has a significantly enhanced stability due to containing the certain amount of histidine hydrochloride buffer as the non-conventional ingredient. In particular, it can be stored for a long time (e.g. more than 200 days) under the condition of an ultra-low temperature(e.g. not more than -60°C ). It can still be capable of maintaining the activities of the recombinant lentiviral vector which can meet to the requirement in use, when exposed to an organism&#39;s body temperature (for example, 37°C) or the room temperature for a longer time.
The invention discloses a smoking stopping medicine, belonging to the medical technical field, in particular to a smoking stopping medicine by means of traditional Chinese medicine. The medicine consists of the following parts by weight of components: 10-25 portions of panacis quinquefolii radix, amoorcorn tree bark, Atractylodes macrocephala respectively, 10-20 portions of Chinese angelica, 5-15 portions of pericarpium citri reticulatae, 15-25 portions of liquorice, 5-15 portions of rhizoma gastrodiae, 10-25 portions of fritillaria roylei hooker and 10-25 portions of radix astragali. By using the illness field caused by a plurality of factors in pathological changes of human body, that is, simulation acupuncture and moxibustion of low-frequency electronic pulse therapeutic apparatus, infrared ray heating and field effect magneto-therapy, a substance of &#39;opium peptide&#39; can be reproduced by human brain, which can restrain and remove the addiction of the human body to nicotine and craving for tobacco. The smoking stopping liquid of the invention is spread on the acupuncture points of smoking stopping. then the electrodes of the low-frequency electronic pulse therapeutic apparatus is arranged on the acupuncture points coated with smoking stopping liquid and the power is switched on to lead in the smoking stopping liquid. By doing twice a day for successive two to three days, the smoking addiction can be given up. The invention has the advantages of low price, prominent effect, short duration and free from rebouncing.
PURPOSE:The titled composition useful as a water repellent, etc., having improved stability, obtained by emulsifying or solubilizing a silicone oil in the presence of protein, protein decomposition product, surface active agent, etc. in a polyhydroxy compound or its aqueous solution. CONSTITUTION:&lt;=90wt%, preferably 30-70wt% based on total emulsion or solution of silicone oil (e.g., straight-chain methylsilicone oil, etc.) is emulsified or solubilized with stirring in the presence of &gt;=0.05, especially &lt;=5wt% based on total amount with solution of protein (e.g., sodium caseinate, etc.), protein decomposition product (decomposition product by protease, etc.) and/or a surface active agent in &gt;=30wt% based on total amount with protein, etc. of a polyhydroxy compound (e.g., propylene glycol, etc.) or its aqueous solution. The silicone oil is preferably blended with a solution of the polyhydroy compound kept at temperature to make it liquid. The composition is easily emulsified or dispersed into water only by adding it to water with stirring.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a safe and low-cost zinc absorption accelerator accelerating the absorption of zinc into bodies because an abnormality in taste and loss of growth are caused by deficiency of zinc absorption, which is a problem in recent years, and to provide a food having accelerating actions on zinc absorption.  &lt;P&gt;SOLUTION: The zinc absorption accelerator is composed of a scallop mantle or a processed product obtained from the scallop mantle as a raw material. The zinc absorption accelerator can be used by ingestion together with a food or formulation in the food. The zinc absorption accelerator, together with the zinc, is preferably formulated in the food. The scallop mantle irreversibly adsorbing the zinc can be utilized as the zinc absorption accelerator or a food material having accelerating effects on the zinc absorption.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
A calorie balance system is designed for consumers who are interested in having a proper and adequate diet while monitoring daily activities. Disclosed embodiments enable consumers to be continuously aware of their caloric intake and to compare their caloric intake with current calories expended. Calories burned or expended may be measured by fitness tracking devices. Enabled utensils such as cups, spoons and forks are equipped with means of wireless communication, an accelerometer, a three axis slope meter sensor, a microcontroller, a scale, an analogue to digital converter and a microcontroller. Enabled utensils measure the weight of food consumed are report to the consumer&#39;s personal electronic device. The system is further enabled by consumers talking to an enabled utensil to report the type of food being consumed. The reported food weight is mapped to the type of food consumed and relevant food data is displayed.
This Personal Vaccine is for the treatment of AIDS (Acquired Immunity Deficiency Syndrome).  It involves the extraction of a blood sample from the AIDS-infected person.  The live HIV virus will then be removed from the sample and killed. This dead HIV virus will be stored as a vaccine and injected back to the same infected person as a Personal Vaccine. This is called a Personal Vaccine because it uses the very same HIV virus (now dead) from the infected person (the host), to treat that person&#39;s AIDS. This procedure is also applicable for the treatment of people, as well as animals infected by diseases caused by viruses. When this Personal Vaccine, containing the infected person&#39;s dead virus, is applied to him, his healthy white cells, or antibodies will recognize the dead virus. Hence, when the antibodies or white blood cells come in contact with the live HIV virus, these antibodies or white blood cells, will recognize the live HIV viruses as harmful and a threat to the person&#39;s (the host) body. This will cause the antibodies to fight the HIV viruses presently destroying the host&#39;s immune system.
PURPOSE:To obtain interferon (IF) as an antiviral agent, antitumor agent, cell prolification inhibitor and immunosuppressant in high yield, by cultivating a microorganism having a developing vector in which a gene capable of producing IF incorporated therein in a specific synthetic culture medium. CONSTITUTION:A microorganism having a developing vector having a gene capable of producing interferon (IF), e.g. human leukocytic IF gene, human immunological IF gene, etc. incorporated therein is cultivated in a synthetic culture medium containing preferably 0.1-10g/l L-glutamic acid and preferably 10&lt;-5&gt;-10&lt;-3&gt;mol/l iron ion source preferably at 5-7.5 culture medium pH and 20- 42 deg.C for 3-72hr. IF is then collected from the resultant culture. Preferably, a Zn ion source and a Cu ion source in an amount of respectively 10&lt;-5&gt;-10&lt;-3&gt;mol/l are added to the culture medium.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide safe and effective approach for increasing immunogenicity of widely various antigens.  &lt;P&gt;SOLUTION: Compositions for mucosal delivery including hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, are provided. Methods for making the compositions, as well as methods of immunization using the same are also provided. Generally, a bioadhesive polymer system is provided. Particularly, use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants is also provided.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
FIELD: medicine. 
     SUBSTANCE: invention refers to medicine, namely recreation therapy, and may be used for human health improvement. That is ensured by traditional medical examination of the patient. The findings are used to draw up the rehabilitation program including body cleansing, intestine and liver purification, physical exercises. One week before the beginning of the rehabilitation program, the patient starts separate nutrition with preferential vegetable food and dairy products, limited consumption of salt, alcohol and sugar. One day before the rehabilitation program, a fasting day is kept with taking 1% kephir or fresh apple juice. Further, on the first two days of the three-day program or on the first four days of the seven-day program, the body is cleansed by keeping a juice diet. The juice diet contains fresh vegetable and fruit juices, herbal infusions and mineral water. Water is unlimited. On the first day of the cleansing program, the intestine is purified with the preparation Fortrans. Starting from the first day the liver and gall bladder are cleansed with using herbal and saline choleretics for four days of the 7-day program and for two days of the 3-day program. That is combined with paradoxical respiration by Strelnikova&#39;s technique and hydrotherapy. Physical exercises involve physical loads on a cardio-vascular machine, one training as prescribed by the doctor - yoga, pilates, chi gong, water aerobics or hypoxi capsule. Therapeutic massage and lymph drainage massage follow. Then body-detox, ozone therapy, collagenarium procedures are performed. Cold training procedures involve Linear Kneipp, saunas, swimming pool, turpentine bathes. Bathing and cold training procedures are followed by pilling and algae wraps. From the 5 th  day of the 7-day program, or from the 3 rd  day of the 3-day program, the diet involves water cereals, vegetable and fruit salads, vegetable fast soups. 
     EFFECT: method provides effective patient&#39;s health recovery, namely weight loss, health improvement, blood value normalisation, formation behavioural model of health preservation over a shortest possible period of time. 
     3 tbl
Pharmaceutical compositions comprising, and methods using, adrenergic compounds and complement compounds. Embodiments include compositions comprising 1 subefficacious amount of an adrenergic compounds; and a safe an d effective amount of a complement to said adrenergic compound. Other embodiments include compositions comprising: (a) a safe and effective amount  of an adrenergic compound; and (b) a complement to said adrenergic compound,  selected from the group consisting of a hyperpreserving amount of an ascorbate, a safe and effective amount of an opioid, a hyperpreserving amoun t of a polycarboxylic acid chelater, a safe and effective amount of D-ribose a nd adenosine derivatives, and mixture thereof. Methods are also provided for regulating an adrenergic receptor in a human or other animal, comprising the  administration of: (c) a low dose of an adrenergic compound; and (d) a safe and effective amount of a complement to said adrenergic compound. Preferably , the adrenergic compound is a catecholamine. Preferred complements include ascorbates, particularly ascorbic acid. Methods include the treatment of neurological disorders, hypotension, forward failure, backward failure, congestive heart failure, shock, hypertension, hemmorhage, disorders associated with anesthesia, chronic obstructive pulmonary disease, asthma, colic, Crohn&#39;s disease, anaphylaxis, interstitial cystitis, overactive bladd er syndrome, premature labor, myethsenia gravis, and glaucoma.
PURPOSE: To obtain the subject new compound, a specific cephem compound, having a wide range of antimicrobial activity, presenting excellent antimicrobial action on methicillin-resistant Staphylococcus aureus(MRSA) and Pseudomonas bacteria, thus useful as e.g. an antimlcrobial agent. CONSTITUTION: This new cephem compound (ester, salt) is expressed by formula I [R&lt;1&gt; is a (protected) amino; R&lt;2&gt; is H car a group linked via a carbon atom; A&lt;+&gt; is a substituted group of e.g. formula II (B is a six-membered aromatic heterocycle with one or two heteroatoms being N; R&lt;3&gt; is a hydrocarbon)]. This compound has excellent antimicrobial effect on a wide range of Gram-positive and Gramnegative bacteria, esp. Staphylococcus aureus, MRSA and Pseudomonas bacteria, etc., therefore being useful as e.g. an antimicrobial agent. This compound is obtained by reaction of a 7-amino-3-cephem-4-carboxylic acid compound of formula III with a 1,2,4-thiadiazol-3-yl-3-iminoacetic acid derivative of formula IV.